EBS - Emergent BioSolutions: Still A Bargain Regardless Of Diminished Growth Forecasts
- Emergent BioSolutions has been an exiled ticker following the vaccine mix-up at the company’s Bayview Facility last year.
- Although the company has addressed the issues in Bayview, it looks as if the market has expelled EBS as a good investment at this point in time.
- I still believe EBS is still a bargain at these prices considering their projected 2021 earnings, product sales, pipeline candidates, and the ticker’s current valuation.
- As a result, I am looking to recommence my accumulation of EBS in anticipation the market will ultimately recognize the disparity and will eventually value the ticker in line with its peers.
For further details see:
Emergent BioSolutions: Still A Bargain Regardless Of Diminished Growth Forecasts